Literature DB >> 9041433

Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis.

E Hilton1, A Tramontano, J DeVoti, S K Sood.   

Abstract

Forty-six patients with late Lyme disease who were considered improved or cured following treatment were monitored by immunoglobin M (IgM) immunoblotting (mean monitoring period, 27.6 months). There was a persistent IgM response in 32 (97%) of 33 initially positive patients. All but three showed a consistent number, type, and intensity of IgM bands over the entire follow-up period. IgM immunoblotting may not be useful for monitoring the response to treatment of Lyme borreliosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041433      PMCID: PMC229671          DOI: 10.1128/jcm.35.3.774-776.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population.

Authors:  A C Steere; E Taylor; M L Wilson; J F Levine; A Spielman
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

2.  Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.

Authors:  S M Engstrom; E Shoop; R C Johnson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

3.  Antibody response in Lyme disease: evaluation of diagnostic tests.

Authors:  J E Craft; R L Grodzicki; A C Steere
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

4.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

5.  The early clinical manifestations of Lyme disease.

Authors:  A C Steere; N H Bartenhagen; J E Craft; G J Hutchinson; J H Newman; D W Rahn; L H Sigal; P N Spieler; K S Stenn; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

6.  Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection.

Authors:  B P Fung; G L McHugh; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Immunoglobulin M immunoblot for diagnosis of Borrelia burgdorferi infection in patients with acute facial palsy.

Authors:  V K Jain; E Hilton; J Maytal; G Dorante; N T Ilowite; S K Sood
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

8.  Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi.

Authors:  B Ma; B Christen; D Leung; C Vigo-Pelfrey
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

9.  Western blotting in the serodiagnosis of Lyme disease.

Authors:  F Dressler; J A Whalen; B N Reinhardt; A C Steere
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Interpretation of immunoblot in pediatric Lyme arthritis.

Authors:  S K Sood; L S Zemel; N T Ilowite
Journal:  J Rheumatol       Date:  1995-04       Impact factor: 4.666

View more
  15 in total

Review 1.  [Neuroborreliosis - Diagnostics, treatment and course].

Authors:  R Dersch; S Rauer
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

2.  Lyme disease.

Authors:  Eugene D Shapiro
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

Review 3.  Clinical practice. Lyme disease.

Authors:  Eugene D Shapiro
Journal:  N Engl J Med       Date:  2014-05-01       Impact factor: 91.245

4.  Use of serum immune complexes in a new test that accurately confirms early Lyme disease and active infection with Borrelia burgdorferi.

Authors:  M Brunner; L H Sigal
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  Dynamic longitudinal antibody responses during Borrelia burgdorferi infection and antibiotic treatment of rhesus macaques.

Authors:  Monica E Embers; Nicole R Hasenkampf; Mary B Jacobs; Mario T Philipp
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

6.  Effects of vlsE complementation on the infectivity of Borrelia burgdorferi lacking the linear plasmid lp28-1.

Authors:  Matthew B Lawrenz; R Mark Wooten; Steven J Norris
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Effect of complement component C3 deficiency on experimental Lyme borreliosis in mice.

Authors:  Matthew B Lawrenz; R Mark Wooten; James F Zachary; Scott M Drouin; Janis J Weis; Rick A Wetsel; Steven J Norris
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 8.  Diagnosis, treatment, and prevention of Lyme disease in children.

Authors:  Stephen C Eppes
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 9.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

10.  Detailed analysis of sequence changes occurring during vlsE antigenic variation in the mouse model of Borrelia burgdorferi infection.

Authors:  Loïc Coutte; Douglas J Botkin; Lihui Gao; Steven J Norris
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.